BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 17341484)

  • 1. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility.
    Johnson N; Fletcher O; Palles C; Rudd M; Webb E; Sellick G; dos Santos Silva I; McCormack V; Gibson L; Fraser A; Leonard A; Gilham C; Tavtigian SV; Ashworth A; Houlston R; Peto J
    Hum Mol Genet; 2007 May; 16(9):1051-7. PubMed ID: 17341484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk.
    Baynes C; Healey CS; Pooley KA; Scollen S; Luben RN; Thompson DJ; Pharoah PD; Easton DF; Ponder BA; Dunning AM;
    Breast Cancer Res; 2007; 9(2):R27. PubMed ID: 17428325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.
    Damiola F; Pertesi M; Oliver J; Le Calvez-Kelm F; Voegele C; Young EL; Robinot N; Forey N; Durand G; Vallée MP; Tao K; Roane TC; Williams GJ; Hopper JL; Southey MC; Andrulis IL; John EM; Goldgar DE; Lesueur F; Tavtigian SV
    Breast Cancer Res; 2014 Jun; 16(3):R58. PubMed ID: 24894818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
    Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
    JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-gene interactions in breast cancer susceptibility.
    Turnbull C; Seal S; Renwick A; Warren-Perry M; Hughes D; Elliott A; Pernet D; Peock S; Adlard JW; Barwell J; Berg J; Brady AF; Brewer C; Brice G; Chapman C; Cook J; Davidson R; Donaldson A; Douglas F; Greenhalgh L; Henderson A; Izatt L; Kumar A; Lalloo F; Miedzybrodzka Z; Morrison PJ; Paterson J; Porteous M; Rogers MT; Shanley S; Walker L; ; Ahmed M; Eccles D; Evans DG; Donnelly P; Easton DF; Stratton MR; Rahman N
    Hum Mol Genet; 2012 Feb; 21(4):958-62. PubMed ID: 22072393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia.
    Rudd MF; Sellick GS; Webb EL; Catovsky D; Houlston RS
    Blood; 2006 Jul; 108(2):638-44. PubMed ID: 16574953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.
    Rebbeck TR; Mitra N; Domchek SM; Wan F; Chuai S; Friebel TM; Panossian S; Spurdle A; Chenevix-Trench G; ; Singer CF; Pfeiler G; Neuhausen SL; Lynch HT; Garber JE; Weitzel JN; Isaacs C; Couch F; Narod SA; Rubinstein WS; Tomlinson GE; Ganz PA; Olopade OI; Tung N; Blum JL; Greenberg R; Nathanson KL; Daly MB
    Cancer Res; 2009 Jul; 69(14):5801-10. PubMed ID: 19584272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
    Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for ATM sequence alterations in African-American women diagnosed with breast cancer.
    Hirsch AE; Atencio DP; Rosenstein BS
    Breast Cancer Res Treat; 2008 Jan; 107(1):139-44. PubMed ID: 17333338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten genes for inherited breast cancer.
    Walsh T; King MC
    Cancer Cell; 2007 Feb; 11(2):103-5. PubMed ID: 17292821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational advances regarding hereditary breast cancer syndromes.
    Gage M; Wattendorf D; Henry LR
    J Surg Oncol; 2012 Apr; 105(5):444-51. PubMed ID: 22441895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
    Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
    J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
    Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
    J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry.
    Graña B; Fachal L; Darder E; Balmaña J; Ramón Y Cajal T; Blanco I; Torres A; Lázaro C; Diez O; Alonso C; Santamariña M; Velasco A; Teulé A; Lasa A; Blanco A; Izquierdo A; Borràs J; Gutiérrez-Enríquez S; Vega A; Brunet J
    Breast Cancer Res Treat; 2011 Jul; 128(2):573-9. PubMed ID: 21445571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study.
    Einarsdóttir K; Rosenberg LU; Humphreys K; Bonnard C; Palmgren J; Li Y; Li Y; Chia KS; Liu ET; Hall P; Liu J; Wedrén S
    Breast Cancer Res; 2006; 8(6):R67. PubMed ID: 17132159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.
    Antoniou AC; Kartsonaki C; Sinilnikova OM; Soucy P; McGuffog L; Healey S; Lee A; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Cattaneo E; Barile M; Pensotti V; Pasini B; Dolcetti R; Giannini G; Putignano AL; Varesco L; Radice P; Mai PL; Greene MH; Andrulis IL; Glendon G; Ozcelik H; Thomassen M; Gerdes AM; Kruse TA; Birk Jensen U; Crüger DG; Caligo MA; Laitman Y; Milgrom R; Kaufman B; Paluch-Shimon S; Friedman E; Loman N; Harbst K; Lindblom A; Arver B; Ehrencrona H; Melin B; ; Nathanson KL; Domchek SM; Rebbeck T; Jakubowska A; Lubinski J; Gronwald J; Huzarski T; Byrski T; Cybulski C; Gorski B; Osorio A; Ramón y Cajal T; Fostira F; Andrés R; Benitez J; Hamann U; Hogervorst FB; Rookus MA; Hooning MJ; Nelen MR; van der Luijt RB; van Os TA; van Asperen CJ; Devilee P; Meijers-Heijboer HE; Gómez Garcia EB; ; Peock S; Cook M; Frost D; Platte R; Leyland J; Evans DG; Lalloo F; Eeles R; Izatt L; Adlard J; Davidson R; Eccles D; Ong KR; Cook J; Douglas F; Paterson J; Kennedy MJ; Miedzybrodzka Z; ; Godwin A; Stoppa-Lyonnet D; Buecher B; Belotti M; Tirapo C; Mazoyer S; Barjhoux L; Lasset C; Leroux D; Faivre L; Bronner M; Prieur F; Nogues C; Rouleau E; Pujol P; Coupier I; Frénay M; ; Hopper JL; Daly MB; Terry MB; John EM; Buys SS; Yassin Y; Miron A; Goldgar D; ; Singer CF; Tea MK; Pfeiler G; Dressler AC; Hansen Tv; Jønson L; Ejlertsen B; Barkardottir RB; Kirchhoff T; Offit K; Piedmonte M; Rodriguez G; Small L; Boggess J; Blank S; Basil J; Azodi M; Toland AE; Montagna M; Tognazzo S; Agata S; Imyanitov E; Janavicius R; Lazaro C; Blanco I; Pharoah PD; Sucheston L; Karlan BY; Walsh CS; Olah E; Bozsik A; Teo SH; Seldon JL; Beattie MS; van Rensburg EJ; Sluiter MD; Diez O; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Ruehl I; Varon-Mateeva R; Kast K; Deissler H; Niederacher D; Arnold N; Gadzicki D; Schönbuchner I; Caldes T; de la Hoya M; Nevanlinna H; Aittomäki K; Dumont M; Chiquette J; Tischkowitz M; Chen X; Beesley J; Spurdle AB; ; Neuhausen SL; Chun Ding Y; Fredericksen Z; Wang X; Pankratz VS; Couch F; Simard J; Easton DF; Chenevix-Trench G;
    Hum Mol Genet; 2011 Aug; 20(16):3304-21. PubMed ID: 21593217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls.
    Fletcher O; Johnson N; dos Santos Silva I; Orr N; Ashworth A; Nevanlinna H; Heikkinen T; Aittomäki K; Blomqvist C; Burwinkel B; Bartram CR; Meindl A; Schmutzler RK; Cox A; Brock I; Elliott G; Reed MW; Southey MC; Smith L; Spurdle AB; Hopper JL; Couch FJ; Olson JE; Wang X; Fredericksen Z; Schürmann P; Waltes R; Bremer M; Dörk T; Devilee P; van Asperen CJ; Tollenaar RA; Seynaeve C; Hall P; Czene K; Humphreys K; Liu J; Ahmed S; Dunning AM; Maranian M; Pharoah PD; Chenevix-Trench G; ; ; Beesley J; Bogdanova NV; Antonenkova NN; Zalutsky IV; Anton-Culver H; Ziogas A; Brauch H; Ko YD; Hamann U; ; Fasching PA; Strick R; Ekici AB; Beckmann MW; Giles GG; Severi G; Baglietto L; English DR; Milne RL; Benítez J; Arias JI; Pita G; Nordestgaard BG; Bojesen SE; Flyger H; Kang D; Yoo KY; Noh DY; Mannermaa A; Kataja V; Kosma VM; García-Closas M; Chanock S; Lissowska J; Brinton LA; Chang-Claude J; Wang-Gohrke S; Broeks A; Schmidt MK; van Leeuwen FE; Van't Veer LJ; Margolin S; Lindblom A; Humphreys MK; Morrison J; Platte R; Easton DF; Peto J;
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2143-51. PubMed ID: 20826828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.